Fas ligand-induced apoptosis

Annual Review of Genetics

Volumn 33, Issue , 1999, Pages 29-55

  Nagata, Shigekazu ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Cell death; Cytotoxic T lymphocytes; Death factor; Fas; Lymphoproliferation

Indexed keywords

CASPASE; FAS ANTIGEN; PROTEINASE;

APOPTOSIS; CELL DIFFERENTIATION; CELL STRUCTURE; CYTOTOXIC T LYMPHOCYTE; DNA DEGRADATION; ENZYME MECHANISM; GENE MUTATION; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CHROMOSOMES; DNA; FAS LIGAND PROTEIN; HUMANS; MEMBRANE GLYCOPROTEINS; MICE;

EID: 0033396491     PISSN: 00664197     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.genet.33.1.29     Document Type: Review

References (195)

1. 1. Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, et al. 1995. Targeted mutation in the Fas gene causes hyperplasia in the peripheral lymphoid organs and liver. Nat. Genet. 11:294-300
2. 2. Adachi M, Suematsu S, Suda T, Watanabe D, Fukuyama H, et al. 1996. Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc. Natl. Acad. Sci. USA 93:2137-42
3. 3. Adachi M, Watanabe-Fukunaga R, Nagata S. 1993. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc. Natl. Acad. Sci. USA 90: 1756-60
4. 4. Aggarwal BB, Singh S, LaPushin R, Totpal K. 1995. Fas antigen signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor. FEBS Lett. 364:5-8
5. 5. Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, et al. 1993. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 178:2231-35
6. 6. Allen RD, Marshall JD, Roths JB, Sidman CL. 1990. Differences defined by bone marrow transplantation suggest that lpr and gld are mutations of genes encoding an interacting pair of molecules. J. Exp. Med. 172:1367-75
7. 7. Allison J, Georgiou HM, Strasser A, Vaux DL. 1997. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl Acad. Sci. USA 94:3943-47
8. 8. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, et al. 1996. Human ICE/CED-3 protease nomenclature. Cell 87:171
9. 9. Arai H, Chan SY, Bishop DK, Nabel GJ. 1997. Inhibition of the alloantibody response by CD95 ligand. Nat. Med. 3:843-48
10. 10. Arai H, Gordon D, Nabel EG, Nabel GJ. 1997. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA 94:13862-67
11. 11. Ashkenazi A, Dixit VM. 1998. Death receptors: signaling and modulation. Science 281:1305-8
12. 12. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld H-J, et al. 1993. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implication for TNF receptor activation. Cell 73: 431-45
13. 13. Beidler DR, Tewari M, Friesen PD, Poirier G, Dixit VM. 1995. The baculovirus p35 protein inhibits Fas- and tumor necrosis factor-induced apoptosis. J. Biol. Chem. 270:16526-28
14. 14. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. 1995. A role for CD95 ligand in preventing graft rejection. Nature 377:630-32
15. 15. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, Weissberg P. 1998. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282:290-93
16. 16. Bettinardi A, Brugnoni D, Quiros-Roldan E, Malagoli A, La Gratta S, et al. 1997. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood 89:902-9
17. 17. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, et al. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385:729-33
18. 18. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. 1996. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85:803-15
19. 19. Bonfoco E, Stuart PM, Branner T, Lin T, Griffith TS, et al. 1998. Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity 9:711-20
20. 20. Bossi G, Griffiths GM. 1999. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat. Med. 5: 90-96
21. 21. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, et al. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441-44
22. 22. Canale V, Smith C. 1967. Chronic lymphadenopathy simulating malignant lymphoma. J. Pediatr. 70:891-99
23. 23. Cardi G, Heaney JA, Schned AR, Ernstoff MS. 1998. Expression of Fas(APO-1/ CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res. 58:2078-80
24. 24. Cascino I, Fiucci G, Papoff G, Ruberti G. 1995. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol. 154:2706-13
25. 25. Cecconi F, Alvarez-Bolado G, Meyer BI, Roth KA, Grass P. 1998. Apafl (CED-4 homolog) regulates programmed cell death in mammalian development. Cell 94:727-37
26. 26. Chan H, Bartos DP, Owen-Schaub LB. 1999. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-κB p50-p65 recruitment. Mol. Cell. Biol. 2098-108
27. 27. Chang HY, Nishitoh H, Yang X, Ichijo H, Baltimore D. 1998. Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science 281:1860-63
28. 28. Chang HY, Yang X, Baltimore D. 1999. Dissecting Fas signaling with an altered-specificity death-domain mutant: requirement of FADD binding for apoptosis but not jun N-terminal kinase activation. Proc. Natl. Acad. Sci. USA 96:1252-56
29. 29. Chen JJ, Sun Y, Nabel GJ. 1998. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282:1714-17
30. 30. Chervonsky AV, Wang Y, Wong FS, Visintin I, Flavell RA. 1997. The role of Fas in autoimmune diabetes. Cell 89:17-24
31. 31. Chinnaiyan AM, Dixit VM. 1996. The cell-death machine. Curr. Biol. 6:555-62
32. 32. Chu K, Niu X-H, Williams L. 1995. A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis. Proc. Natl. Acad. Sci. USA 92:11894-98
33. 33. Cohen PL, Eisenberg RA. 1991. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9:243-69
34. 34. Cuppen E, Nagata S, Wieringa B, Hendriks W. 1997. No evidence for involvement of mouse protein-tyrosine phosphatase-BAS-like Fas-associated phosphatase-1 in Fas-mediated apoptosis. J. Biol. Chem. 272: 30215-20
35. 35. Debatin K-M, Goldman CK, Waldmann TA, Krammer PH. 1993. APO-1 induced apoptosis of leukemia cells from patients with ATL. Blood 81:2972-77
36. +T cells. Nat. Med. 4:1377-82
37. 37. Dhein J, Daniel PT, Trauth BC, Oehm A, Moller P, Krammer PH. 1992. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J. Immunol. 149:3166-73
38. 38. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438-41
39. 39. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. 1996. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med. 335:1643-49
40. 40. Ellis HM, Horvitz H. 1986. Genetic control of programmed cell death in the nematode C. elegans. Cell 44:817-29
41. 41. Ellis RE, Yuan J, Horvitz HR. 1991. Mechanisms and functions of cell death. Annu. Rev. Cell Biol. 7:663-98
42. 42. Enari M, Hase A, Nagata S. 1995. Apoptosis by a cytosolic extract from Fas-activated cells. EMBO J. 14:5201-8
43. 43. Enari M, Hug H, Nagata S. 1995. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375:78-81
44. 44. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. 1998. Acaspase-activated DNase that degrades DNA during apoptosis and its inhibitor ICAD. Nature 391:43-50
45. 45. Enari M, Talanian RV, Wong WW, Nagata S. 1996. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 380:723-26
46. 46. Faris M, Kokot N, Latinis K, Kasibhatla S, Green DR, et al. 1998. The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J. Immunol 160:134-44
47. 47. Fiedler P, Scaetzlein CE, Eibel H. 1998. Constitutive expression of FasL in thyrocytes. Science 279:2015a
48. 48. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, et al. 1995. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935-46
49. 49. Friesen C, Herr I, Krammer PH, Debatin KM. 1996. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2:574-77
50. 50. Fukuyama H, Adachi M, Suematsu S, Miwa K, Suda T, et al. 1998. Transgenic expression of Fas in T cells blocks lymphoproliferation but not autoimmune disease in MRL-lpr mice. J. Immunol. 160:3805-11
51. 51. Gonzalez-Garcia A, Rborlado L, Leonardo E, Merida I, Martinez AC, Carrera AC. 1997. Lck is necessary and sufficient for Fas-ligand expression and apoptotic cell death in mature cycling T cells. J. Immunol. 158:4104-12
52. 52. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-92
53. 53. Gronbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, et al. 1998. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 92: 3018-24
54. 54. Gulbin E, Bissonnette R, Mahboubi A, Martin S, Nishioka W, et al. 1995. Fas-induced apoptosis is mediated via a ceramide-initiated ras signaling pathway. Immunity 2:341-51
55. 55. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, et al. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363-66
56. 56. Hakem R, Hakem A, Duncan GS, Henderson JT, Woo M, et al. 1998. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 94:339-52
57. 57. Hannun YA. 1996. Functions of ceramide in coordinating cellular responses to stress. Science 274:1855-59
58. 58. Hasegawa D, Kojinia S, Tatsumi E, Hayakawa A, Kosaka Y, et al. 1998. Elevation of the serum Fas ligand in patients with hemophagocytic syndrome and Diamond-Blackfan anemia. Blood 91:2793-99
59. 59. Hattori K, Hirano T, Miyajinia H, Yamakawa N, Tateno M, et al. 1998. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 91:4051-55
60. 60. Heldin C-H. 1995. Dimerization of cell surface receptors in signal transduction. Cell 80:213-23
61. 61. Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, et al. 1998. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J. Exp. Med. 187:587-600
62. 62. Hofmann K, Dixit VM. 1998. Ceramide in apoptosis - does it really matter? Trends Biochem. Sci. 23:374-77
63. 63. Hsu H, Huang J, Shu H-B, Baichwal V, Goeddel D. 1996. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4: 387-96
64. 64. Hsu S-C, Wu C-C, Luh T-Y, Chou C-K, Han S-H, Lai M-Z. 1998. Apoptosis signal of Fas is not mediated by ceramide. Blood 91:2658-63
65. 65. Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW. 1996. NMR structure and mutagenesis of the Fas (Apo-1/ CD95) death domain. Nature 384:638-41
66. 66. Hueber AO, Zornig M, Lyon D, Suda T, Nagata S, Evan GI. 1997. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 278:1305-9
67. 67. Inazawa J, Itoh N, Abe T, Nagata S. 1992. Assigmnent of the human Fas antigen gene (FAS) to 10q24.1.Genomics 14:821-22
68. 68. Itoh N, Imagawa A, Hanafusa T, Waguri M, Yamamoto K, et al. 1997. Requirement of Fas for the development of autoimmune diabetes in non-obese diabetic mice. J. Exp. Med. 186:613-18
69. 69. Itoh N, Nagata S. 1993. A novel protein domain required for apoptosis: mutational analysis of human Fas antigen. J. Biol. Chem. 268:10932-37
70. 70. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, et al. 1991. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233-43
71. 71. Ju S-T, Panka DJ, Cui H, Ettinger R, El-Khatib M, et al. 1995. Fas (CD95)/FasL interaction required for programmed cell death after T-cell activation. Nature 373: 444-48
72. 72. Juo P, Kuo CJ, Yuan J, Blenis J. 1998. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr. Biol. 8:1001-8
73. 73. Kanda Y, Tanaka Y, Shirakawa K, Yatomi T, Nakamura N, et al. 1998. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant. 22:751-54
74. 74. Kang S, Hofmann A, Le D, Springer M, Stock P, Blau H. 1997. Immune response and myoblasts that express Fas ligand. Science 278:1322-24
75. 75. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, et al. 1997. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3:738-43
76. 76. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. 1999. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat. Med. 5:292-97
77. 77. Kasahara Y, Wada T, Niida Y, Yachie A, Seki H, et al. 1998. Novel Fas (CD95/ APO-1) mutations in infants with a lymphoproliferative disorder. Int. Immunol. 10:195-202
78. 78. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green D. 1998. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocyte s via the activation o f NF-κB and AP-1. Mol. Cell 1:543-51
79. 79. Kasibhatla S, Genestier L, Green DR. 1999. Regulation of Fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor κB. J. Biol. Chem. 274:987-92
80. 79a. Kataoka T, Schroter M, Hahne M, Schneider P, Irmler M, et al. 1998. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J. Immunol. 161:3936-42
81. 80. Katsikis P, Wunderlich E, Smith C, Herzenberg L, Herzenberg L. 1995. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J. Exp. Med. 181:2029-36
82. 81. Kawahara A, Ohsawa Y, Matsumura H, Uchiyama Y, Nagata S. 1998. Caspase-independent cell killing by Fas-associated protein with death domain. J. Cell Biol. 143:1353-60
83. 82. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, et al. 1995. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182:1777-83
84. 83. Kerr JF, Wyllie AH, Currie AR. 1972. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26:239-57
85. 84. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, et al. 1995. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins from a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14:5579-88
86. 85. Kishimoto H, Sprent J. 1997. Negative selection in the thymus includes semimature T cells. J. Exp. Med. 185:263-71
87. 86. Kishimoto H, Surh CD, Sprent J. 1998. A role for Fas in negative selection of thymocytes in vivo. J. Exp. Med. 187:1427-38
88. 87. Kolesnick RN, Kronke M. 1998. Regulation of ceramide production and apoptosis. Annu. Rev. Physiol. 60:643-65
89. 88. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. 1997. Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 3:409-13
90. 89. Krammer P. 1999. CD95(APO-1/Fas)-mediated apoptosis: Live and let die. Adv. Immunol. 71:163-210
91. 90. Kuida K, Haydar TF, Kuan CY, Gu Y, Taya C, et al. 1998. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 94:325-37
92. 91. Lagarkova MA, larovaia OV, Razin SV. 1995. Large-scale fragmentation of mammalian DNA in the course of apoptosis proceeds via excision of chromosomal DNA loops and their oligomers. J. Biol. Chem. 270:20239-41
93. 92. Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS. 1997. Mutations in the Fas antigen in patients with multiple myeloma. Blood 90:4266-70
94. 93. Lau HT, Yu M, Fontana A, Stoeckert CJ Jr. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273:109-12
95. 94. Le Deist F, Emile JF, Rieux-Laucat F, Benkerrou M, Roberts I, et al. 1996. Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet 348:719-23
96. 95. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, et al. 1993. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor super-family, in normal and neoplastic cells. Lab. Invest. 69:415-29
97. 96. Li H, Zhu H, Xu CJ, Yuan J. 1998. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501
98. 97. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, et al. 1997. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479-89
99. 98. Lichter P, Walczak H, Weitz S, Behrmann I, Krammer PH. 1992. The human APO-1 (APT) antigen maps to 10q23, a region that is syntenic with mouse chromosome 19. Genomics 14:179-80
100. 99. Liu X, Zou H, Slaughter C, Wang X. 1997. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 89:175-84
101. 100. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. 1998. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94:481-90
102. 101. Maeda A, Aragane Y, Tezuka T. 1998. Expression of CD95 ligand in melanocytic lesions as a diagnostic marker. Br. J. Dermatol. 139:198-206
103. 102. Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P. 1997. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186:785-93
104. 102a. Martin DA, Siegel RM, Zheng L, Lenardo MJ. 1998. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/ MACHalpha1) death signal. J. Biol. Chem. 273:4345-49
105. 103. Matsui K, Fine A, Zhu B, Marshak RA, Ju ST. 1998. Identification of two NF-κB sites in mouse CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma. J. Immunol. 161:3469-73
106. 104. McClure RF, Heppelmann CJ, Paya CV. 1999. Constitutive Fas ligand gene transcription in sertoli cells is regulated by Sp1. J. Biol. Chem. 274:7756-62
107. 105. McIloy D, Sakahira H, Talanian RV, Nagata S. 1999. Involvement of caspase 3-activated DNase in internucleosomal DNA cleavage induced by diverse apoptotic stimuli. Oncogene 18:4401-8
108. 106. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT. 1997. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J. Natl. Cancer Inst. 89:783-89
109. 107. Mittelstadt PR, Ashwell JD. 1998. Cyclosporin A-sensitive transcription factor Egr-3 regulates Fas ligand expression. Mol. Cell. Biol. 18:3744-51
110. 108. Miwa K, Asano M, Iwakura Y, Nagata S, Suda T. 1998. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med. 4:1287-91
111. 109. Moss ML, Catherine Jin S-L, Milla ME, Burkhart W, Carter HL, et al. 1997. Cloning of a disintegrin metalloproteinase that processes precursor tumor-necrosis factor α. Nature 385:733-36
112. 110. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, et al. 1997. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99: 403-13
113. 111. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, et al. 1999. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188:2033-45
114. 112. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, et al. 1996. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85:817-27
115. 113. Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. 1998. An induced proximity model for caspase-8 activation. J. Biol. Chem. 273:2926-30
116. 114. Nagata S. 1997. Apoptosis by death factor. Cell 88:355-365
117. 115. Nagata S, Golstein P. 1995. The Fas death factor. Science 267:1449-56
118. 116. Newton K, Harris AW, Bath ML, Smith KGC, Strasser A. 1998. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 17:706-18
119. 117. Nicholson DW, Thornberry NA. 1997. Caspases: killer proteases. Trends Biochem. Sci. 22:299-306
120. 118. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H. 1997. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum. 40:1126-29
121. 118a. O'Connor L, Strasser A. 1999. Fas, p53, and apoptosis. Science 284:431b
122. 119. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075-82
123. 120. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, et al. 1993. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J. 12:3679-84
124. 121. Ogasawara J, Suda T, Nagata S. 1995. Selective apoptosis of CD4 CD8 thymocytes by the anti-Fas antibody. J. Exp. Med. 181: 485-91
125. 122. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, et al. 1993. Lethal effect of the anti-Fas antibody in mice. Nature 364:806-9
126. 123. Okura T, Gong L, Kamitani T, Wada T, Okura I, et al. 1996. Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J. Immunol. 157:4277-81
127. 124. Oshimi Y, Oda S, Honda Y, Nagata S, Miyazaki S. 1996. Involvement of Fas ligand- and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J. Immunol. 157:2909-15
128. 125. Ottonello L, Tortolina G, Amelotti M, Dallegri F. 1999. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J. Immunol. 162:3601-6
129. 126. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, et al. 1995. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol. 15:3032-40
130. 127. Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G. 1996. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J. Immunol. 156:4622-30
131. 128. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kishkel FC, et al. 1999. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699-703
132. 129. Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC. 1996. Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 87:319-29
133. 130. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Denatin KM, et al. 1995. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347-49
134. 131. Russell JH, Rush B, Weaver C, Wang R. 1993. Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc. Natl. Acad. Sci. USA 90:4409-13
135. 132. Russell JH, Wang R. 1993. Autoimmune gld mutation uncouples suicide and cytokine/proliferation pathways in activated, mature T cells. Eur. J. Immunol. 23:2379-82
136. 133. Sabapathy K, Hu Y, Kallunki T, Schreiber M, David JP, et al. 1999. JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr. Biol. 9:116-25
137. 134. Sabelko KA, Kelly KA, Nahm MH, Cross AH, Russell JH. 1997. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J. Immunol. 159:3096-99
138. 135. Sakahira H, Enari M, Nagata S. 1998. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 391:96-99
139. 135a. Sakahira H, Enari M, Ohsawa Y, Uchiyama Y, Nagata S. 1999. Apoptotic morphological change without DNA fragmentation. Curr. Biol. 9:543-46
140. 136. Sato K, Kimura F, Nakamura Y, Murakami H, Yoshida M, et al. 1996. An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. Br. J. Hematol. 94:379-82
141. 137. Sato T, Irie S, Kitada S, Reed JC. 1995. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 268: 411-15
142. 138. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, et al. 1998. Two CD95 (APO-1/ Fas) signaling pathways. EMBO J. 17: 1675-87
143. 139. Schneider P, Bodmer JL, Holler N, Mattmann C, Scuderi P, et al. 1997. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J. Biol. Chem. 272: 18827-33
144. 140. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, et al. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1205-13
145. 141. Schulze-Osthoff K, Walczak H, Droge W, Krammer PH. 1994. Cell nucleus and DNA fragmentation are not required for apoptosis. J. Cell. Biol. 127:15-20
146. 142. Schwandner R, Wiegmann K, Bernardo K, Kreder D, Kronke M. 1998. TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase. J. Biol. Chem. 273:5916-22
147. 143. Seino K, Iwabuchi K, Kayagaki N, Miyata R, Nagaoka I, et al. 1998. Chemotactic activity of soluble Fas ligand against phagocytes. J. Immunol. 161:4484-88
148. 144. Seino K, Kayagaki N, Okumura K, Yagita H. 1997. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3:165-70
149. 145. Singer GG, Abbas AK. 1994. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1:365-71
150. 146. Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, et al. 1997. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 89:1341-48
151. 147. Stanger BZ, Leder P, Lee T-H, Kim E, Seed B. 1995. RIP: a novel protein containing a death domain that interacts with FAS/APO-1 (CD95) in yeast and causes cell death. Cell 81:513-23
152. 148. Stokes TA, Rymaszewski M, Arscott PA, Wang S-H, Bretz JD, et al. 1998. Constitutive expression of FasL in thyrocytes. Science 279:2015a
153. 149. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, et al. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/ Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med. 2:1361-66
154. 149a. Strasser A, Harris A, Huang D, Krammer P, Cory S. 1995. Bcl-2 and Fas/ APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 14: 6136-47
155. 150. Stroh C, Schulze-Osthoff K. 1998. Death by a thousand cuts: an ever increasing list of caspase substrates. Cell Death Differ. 5:997-1000
156. 151. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA. 1997. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 99:396-402
157. 152. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. 1997. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186:2045-50
158. 153. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, et al. 1995. Expression of the Fas ligand in T-cell-lineage. J. Immunol. 154:3806-13
159. 154. Suda T, Takahashi T, Golstein P, Nagata S. 1993. Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. Cell 75:1169-78
160. 155. Suzuki I, Fink PJ. 1998. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J. Exp. Med. 187:123-28
161. 156. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, et al. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969-76
162. 157. Takahashi T, Tanaka M, Ogasawara J, Suda T, Murakami H, Nagata S. 1996. Swapping between Fas and G-CSF receptor. J. Biol. Chem. 271:17555-60
163. 158. Tanaka M, Itai T, Adachi M, Nagata S. 1998. Down-regulation of Fas ligand by shedding. Nat. Med. 4:31-36
164. 159. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, et al. 1996. Fas ligand in human serum. Nat. Med. 2:317-22
165. 160. Tanaka M, Suda T, Takahashi T, Nagata S. 1995. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14:1129-35
166. 161. Tanaka M, Suda T, Yatomi T, Nakamura N, Nagata S. 1997. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J. Immunol. 158:2303-9
167. 162. Tartaglia LA, Ayres TM, Wong GHW, Goeddel DV. 1993. A novel domain within the 55 kd TNF receptor signals cell death. Cell 74:845-53
168. 163. Tartaglia LA, Goeddel DV. 1992. Two TNF receptors. Immunol. Today 13:151-53
169. 164. Testi R. 1996. Sphingomyelin breakdown and cell fate. Trends Biochem. Sci. 21:468-71
170. 165. Tewari M, Dixit VM. 1995. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J. Biol. Chem. 270:3255-60
171. 166. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, et al. 1992. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 356:768-74
172. 167. Thornberry NA, Lazebnik Y. 1998. Caspases: enemies within. Science 281: 1312-16
173. 168. Ting AT, Pimentel MF, Seed B. 1996. RIP mediates tumor necrosis factor receptor 1 activation of NF-κB but not Fas/APO-1-initiated apoptosis. EMBO J. 15:6189-96
174. 169. Toyozaki T, Hiroe M, Tanaka M, Nagata S, Ohwada H, Marumo F. 1998. Levels of soluble Fas ligand in myocarditis. Am. J. Cardiol. 82:246-48
175. 170. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, et al. 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301-5
176. 171. Vaishnaw AK, Orlinick JR, Chu JL, Krammer PH, Chao MV, Elkon KB. 1999. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J. Clin. Invest. 103:355-63
177. 172. Vandenabeele P, Declercq W, Beyaert R, Fiers W. 1995. Two tumor necrosis factor receptors: structure and function. Trends Cell Biol. 5:392-99
178. 173. Varfolomeev EE, Schuchmann M, Luria V, Chiannikulchai N, Beckmann JS, et al. 1998. Target disruption of the mouse caspase 8 gene abalates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9:267-76
179. 174. Waldner H, Sobel RA, Howard E, Kuchroo VK. 1997. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J. Immunol. 159:3100-3
180. 175. Walsh CM, Wen BG, Chinnaiyan AM, O'Rourke K, Dixit VM, Hedrick SM. 1998. A role for FADD in T cell activation and development. Immunity 8:439-49
181. 176. Wang J, Taniuchi I, Maekawa Y, Howard M, Cooper MD, Watanabe T. 1996. Expression and function of Fas antigen on activated murine B cells. Eur. J. Immunol. 26:92-96
182. 177. Watanabe D, Suda T, Nagata S. 1995. Expression of Fas in B cells of the mouse germinal center and Fas-dependent killing of activated B cells. Int. Immunol. 7:1949-56
183. 178. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-17
184. 179. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, et al. 1992. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148:1274-79
185. 180. Watts JD, Gu M, Polverino AJ, Patterson SD, Aebersold R. 1997. Fas-induced apoptosis of T cells occurs independently of ceramide generation. Proc. Natl. Acad. Sci. USA 94:7292-96
186. 181. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. 1996. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J. Clin. Invest. 98:1107-13
187. 182. Wyllie AH. 1980. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555-56
188. 183. Yang X, Chang HY, Baltimore D. 1998. Autoproteolytic activation of pro-caspases by oligomerization. Mol. Cell 1:319-25
189. 184. Yang X, Khosravi-Far R, Chang HY, Baltimore D. 1997. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 89:1067-76
190. 185. Yeh WC, Pompa JL, McCurrach ME, Shu HB, Elia AJ, et al. 1998. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279:1954-58
191. 186. Yonehara S, Ishii A, Yonehara M. 1989. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down-regulated with the receptor of tumor necrosis factor. J. Exp. Med. 169:1747-56
192. 187. Yoshida H, Kong YY, Yoshida R, Elia AJ, Hakem A, et al. 1998. Apafl is required for mitochondrial pathways of apoptosis and brain development. Cell 94:739-50
193. 188. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. 1993. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme. Cell 75:641-52
194. 189. Zhang J, Cado D, Chen A, Kabra NH, Winoto A. 1998. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/ Mortl. Nature 392:296-300
195. 190. Zhang J, Liu X, Scherer DC, van Kaer L, Wang X, Xu M. 1998. Resistance to DNA fragmentation and chromatin condensation in mice lacking the DNA fragmentation factor 45. Proc. Natl. Acad. Sci. USA 95:12480-85